AHAkira Hirano

Akira Hirano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Akira Hirano has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Tadao Shimizu

    Department of Breast Surgery, Tokyo Women's Medical University Medical Center East, 2-1-10 Nishi-ogu, Arakawa-ku, Tokyo, 116-8567, Japan

    11 shared publications
  • Mari Kamimura

    Department of Breast Surgery, Tokyo Women's Medical University Medical Center East, 2-1-10 Nishi-ogu, Arakawa-ku, Tokyo, 116-8567, Japan

    8 shared publications
  • Kaoru Ogura

    Department of Breast Surgery, Tokyo Women's Medical University Medical Center East, 2-1-10 Nishi-ogu, Arakawa-ku, Tokyo, 116-8567, Japan

    7 shared publications
  • Akinori Hattori

    Department of Breast Surgery, Tokyo Women's Medical University Medical Center East, 2-1-10 Nishi-ogu, Arakawa-ku, Tokyo, 116-8567, Japan

    5 shared publications
  • Aya Matsuoka

    Department of Breast Surgery, Tokyo Women's Medical University Medical Center East, 2-1-10 Nishi-ogu, Arakawa-ku, Tokyo, 116-8567, Japan

    5 shared publications
  • Hiroko Yukawa

    Department of Breast Surgery, Tokyo Women's Medical University Medical Center East, 2-1-10 Nishi-ogu, Arakawa-ku, Tokyo, 116-8567, Japan

    5 shared publications

Latest Publications

  • Open Access

    Effect of adjuvant chemotherapy in patients with ER + /HER2− breast cancer, assessed by propensity score matching: significance of nuclear grade and nodal status

    by Natsuko Tanaka, Akira Hirano, Akinori Hattori, Kaoru Ogura, Mari Kamimura, Hiroaki Inoue, Hiroko Yukawa, Shiho Sakaguchi, Aya Matsuoka, Asaka Kodera, et al.

    Background Survival benefits of chemotherapy (CT) differ among patients with estrogen receptor-positive (ER +) breast cancer. This study investigated the survival benefits of CT for ER + and human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) patients by propensity score matching (PSM). Methods Patients with stages I–IIIER + /HER2− BC were enrolled in this study. The primary endpoints were 5-year recurrence-free survival (RFS) and overall survival (OS) in the non-CT and CT groups of the selected population matched by PS. The PS was analyzed by a logistic regression model with factors those influence provided indication of chemotherapy [tumor size, nuclear grade (NG), progesterone receptor, and nodal status]. Results This study enrolled 895 patients between 2000 and 2015. The median follow-up period was 5.7 years. Overall, the 5-year RFS was 94.3% and 90.1% in the non-CT and CT-treated groups, respectively (p = 0.106). The 5-year OS was 97.5% in the non-CT group and 95.6% in the CT group (p = 0.047). Using PSM, 236 patients were selected. After matching, both the 5-year RFS and the 5-year OS were higher in the CT group than in the non-CT group (96.8% vs. 82.7%, p = 0.003 and 100% vs. 91.9%, p < 0.001, respectively). Particularly in the case of the node negative/NG3 and 1–3 node positive/NG2 patients after PSM, the 5-year RFS was significantly higher in the CT group than in the non-CT group (p = 0.041 and p = 0.006, respectively). Conclusion After PSM, CT significantly improved both the RFS and OS of ER + / HER2− BC patients, especially for node negative/NG3 and 1–3 node positive/NG2 patients.


  • Breast-conserving surgery without radiation in elderly women with early breast cancer

    by Hiroaki Inoue, Akira Hirano, Kaoru Ogura, Mari Kamimura, Akinori Hattori, Hiroko Yukawa, Shiho Sakaguchi, Natsuko Tanaka, Aya Matsuoka, Asaka Kodera, et al.


  • Long‐term effect of exemestane therapy on bone mineral density supported by bisphosphonates: Results of 5‐year adjuvant treatment in postmenopausal women with early‐stage breast cancer

    by Akira Hirano, Hiroaki Inoue, Kaoru Ogura, Akinori Hattori, Hiroko Yukawa, Shiho Sakaguchi, Aya Matsuoka, Natsuko Tanaka, Asaka Kodera, Mari Kamimura, et al.

    Purpose: Unlike anastrozole, the effect of long‐term exemestane (EXE) therapy on bone mineral density (BMD) is still unknown. We assessed changes in BMD from baseline to 5 years of EXE treatment.Methods: Postmenopausal women with endocrine‐responsive breast cancer receiving EXE as adjuvant therapy were enrolled in this study. EXE was administered for 5 years. The BMD of the lumbar spine (LS) and femoral neck (FN) was assessed by dual‐energy X‐ray absorptiometry at baseline and after 6 months and 1, 2, 3, 4, 5 and 6 years. Oral bisphosphonate (Bis) treatment was initiated when patients were diagnosed with osteoporosis with a T‐score of −2.5 or lower.Results: Eighty‐one patients were enrolled in the study between 2005 and 2010. The median follow‐up period was 54.9 months. Forty‐two patients were administered Bis. Overall, the BMD of the LS increased by 7.3% from baseline and that of the FN increased by 3.4% with 5 years of EXE treatment. At the sixth year (i.e. 1 year after the treatment), BMD of the LS increased by 7.2% and that of the FN increased by 5.7%. Furthermore, the BMD of the FN increased by 12.0% in patients treated upfront with Bis and by 1.2% in those not treated with Bis (P = 0.0262). Fractures developed in nine patients (11.1%) and seven (8.6%) had fragility fractures.Conclusion: Oral Bis improves BMD of the FN in patients with osteoporosis. Five‐year EXE treatment with proper addition of Bis helps maintain the BMD of the LS and FN at the sixth year.


    • 1 November 2017
      • Vol. 44  (12) , 1200-1202

    [Treatment Out Come of Eribulin in Patients with Advanced or Metastatic Breast Cancer Who Resistant to Anthracycline and Taxane].

    by Natsuko Tanaka, Kaoru Ogura, Akinori Hattori, Hiroaki Inoue, Hiroko Yukawa, Shiho Sakaguchi, Aya Matsuoka, Asaka Kodera, Yoshihiko Naritaka, Akira Hirano

    This retrospective observational study contains advanced or metastatic breast cancer female patients who pretreated with anthracycline and/or taxane received eribulin(ERI)mesylate. The primary endpoint was the progressionfree survival(PFS)and secondary endopoints were objective response rate(ORR), clinical benefit rate(CBR), overall survival (OS), and post-progression survival(PPS). A total of 32 patients underwent chemotherapy cycles(median 3; range 1-9 cycles). The ORR was 15.6% and the CBR was 31.3%. The median PFS, OS and PPS were 2.9 months, 8.5 months, 5.6 months respectively. The OS, PPS for relative dose intensity(RDI)<85% and RDI≥85% were 7.2 months, 3.4 months and 14.5 months, 11.4 months, respectively(p=0.005, 0.004). In multivariate analysis for OS and PPS, the visceral disease, total dose of ERI and RDI correlated with OS and PPS. The most frequent treatment-related Grade 3/4 adverse events was neutropenia( 56%). No Grade 3 and 4 peripheral sensory neuropathy was occurred. ERI exhibited efficacy and tolera- bility in patients with heavily pretreated A/MBC. The total dose and RDI of ERI would induce favorable effect for prognosis.


  • Changes in bone mineral density during 5 years of adjuvant exemestane therapy in postmenopausal women with early breast cancer.

    by Akira Hirano, Hiroaki Inoue, Kaoru Ogura, Akinori Hattori, Hiroko Yukawa, Shiho Sakaguchi, Aya Matsuoka, Mari Kamimura, Jun Kinoshita, Yoshihiko Naritaka, et al.

    E12003 Background: Adjuvant therapy with aromatase inhibitors (AI) is associated with increased bone loss in postmenopausal women. The effect of 5 years of treatment with anastrozole on bone mineral density (BMD) was previously reported (Eastell R. J Clin Oncol 26:1051-1058, 2008). However, the effect of long-term (more than 2 years) therapy with exemestane (EXE) on BMD is still unknown. We assessed changes in BMD from baseline to 5 years of treatment in patients receiving EXE as initial adjuvant therapy with/without oral bisphosphonates (Bis). Methods: Postmenopausal women with endocrine-responsive breast cancer receiving EXE as adjuvant therapy at our hospital since 2005 were enrolled in this study. BMD was assessed by dual-energy X-ray absorptiometry at baseline and after 6, 12, 24, 36, 48, and 60 months. Oral Bis (risedronate or alendronate) treatment was initiated when patients were diagnosed with osteoporosis with a T-score of 2.5 or lower. Observation was censored when treatment of EXE was stopped because of relapse or other diseases. Results: Eighty-one patients were enrolled in the study between 2005 and 2010. Patients’ median age was 67 years, and the median follow-up period was 60 months. Forty-two patients were administered Bis (upfront use of Bis: 28 patients; delayed use of Bis: 14 patients). Within 6 months of hormone therapy, BMD increased by 2.4% from baseline in the lumbar spine and decreased by 0.5% in the femoral neck. After 5 years of treatment, however, BMD had increased by 7.8% in the lumbar spine and by 3.4% in the femoral neck. In patients treated with upfront Bis (n = 28), a 5.7% increase in BMD from baseline was noted in the lumbar spine, whereas in those without Bis (n = 39), BMD decreased by 1.8% from baseline within 12 months (P < 0.0001). Fractures were observed in 10 patients (12.3%), and 8 (9.9%) had fragility-related fractures. Conclusions: Oral Bis improves BMD in the lumbar spine among patients with osteoporosis. Treatment with EXE for 5 years with proper use of Bis maintains BMD in the lumbar spine and femoral neck. Clinical trial information: UMIN000020499.

    • 1 May 2011
      • Vol. 38  (5) , 771-6

    [Responses to primary systemic therapy for breast cancer as assessed by hormone receptor and HER2 status].

    by Akira Hirano, Tadao Shimizu, Mari Kamimura, Kaoru Ogura, Naomi Kim, Yumika Setoguchi, Fumie Okubo, Jun Kinoshita, Kenji Ogawa, Mariko Fujibayashi

    The aim of this study was to investigate responses to primary systemic therapy (PST) for breast cancer, by hormone receptor (HR) and HER2 status. This study included 107 women with T>3 cm and/or node-positive breast cancer who received PST at this department between March 2004 and January 2009. Treatment with epirubicin and cyclophosphamide (EC) followed by docetaxel (DTX) therapy was undertaken up to December 2005. From January 2006, EC followed by weekly paclitaxel (PTX) with or without trastuzumab (T) therapy was performed. From February 2008 and thereafter, the EC-PTX-T therapy was continued in HER2-positive patients, whereas the preceding EC-DTX therapy was administered in HER2-negative patients. Clinical responses of the 107 patients (56 were treated with EC-DTX, 37 with EC-PTX, and 14 with EC-PTX-T) were as follows: CR was achieved in 18 patients, PR in 74 patients, SD in 12 patients, and PD in 3 patients, with a response rate of 86. 0%. Histologically, 14 patients(13. 2%)had pathological CR(pCR)in a limited sense. When these patients were further divided according to HR status, those positive for both estrogen receptor (ER) and progesterone receptor (PgR) accounted for 1. 8%, those positive for ER and negative for PgR accounted for 5. 3%, and those negative for both ER and PgR accounted for a significantly higher percentage of 40. 0% (p<0. 0001) . By HER2 status, pCR was achieved at a significantly higher rate (47. 8%) of HER2-positive patients, compared to 3. 6% of HER2-negative patients (p<0. 0001). Common adverse events included Grade 3/4 leukopenia (57. 9%), neutropenia (67. 3%), and Grade 3 febrile neutropenia (11. 2%). The results show that a higher pCR rate can be expected after PST in HR-negative patients and HER2-positive patients. HER2-positive patients would particularly benefit from preoperative anthracycline chemotherapy followed by a taxane combined with trastuzumab.

    • 1 November 2010
      • Vol. 30  (11) , 4665-71

    A phase II study of epirubicin and cyclophosphamide followed by weekly paclitaxel with or without trastuzumab as primary systemic therapy in locally advanced breast cancer.

    by Tadao Shimizu, Akira Hirano, Mari Kamimura, Kaoru Ogura, Naomi Kim, Osamu Watanabe, Jun Kinoshita, Kiyomi Kimura, Kenji Ogawa, Mariko Fujibayashi

    The aim of this study was to evaluate the activity and toxicity of epirubicin and cyclophosphamide followed by weekly paclitaxel with or without trastuzumab as primary systemic therapy in locally advanced breast cancer. Patients with T2-4 (>3 cm) or N1-3 breast cancer received epirubicin (100 mg/m(2)) and cyclophosphamide (600 mg/m(2)) every three weeks for four cycles followed by paclitaxel (80 mg/m(2)) every week for twelve cycles. Trastuzumab (initially 4 mg/kg, then 2 mg/kg) was added to paclitaxel in HER2-positive patients. The primary endpoint was the pathological complete response (pCR) rate in the breast and axilla, and secondary endpoints were the breast-conserving rate and toxicity. Forty-three patients were enrolled into this study and 3 patients withdrew. The pCR rate was 20.0% (95% confidence interval, 10.5-34.8%). Patients with HER2-positive tumours had a significantly higher pCR rate than the others (62.5% vs. 9.4%; p=0.0008). Twenty-four patients (60.0%) underwent breast-conserving surgery. Grade 4 neutropenia was recorded in 30.0% of the patients, and febrile neutropenia occurred in 7 patients (17.5%). Epirubicin and cyclophosphamide followed by weekly paclitaxel, either with or without trastuzumab, was an active and well-tolerated treatment for locally advanced breast cancer.


    • 1 February 2010
      • Vol. 30  (2) , 581-5

    Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer.

    by Tadao Shimizu, Akira Hirano, Osamu Watanabe, Jun Kinoshita, Kiyomi Kimura, Mari Kamimura, Kaoru Domoto, Naomi Kim, Kenji Ogawa, Mariko Fujibayashi

    A 75-year old woman presented with diffuse left breast enlargement, redness, edema, and a firm palpable lymph node with skin fixation in the left axilla. The tumor was diagnosed as invasive ductal carcinoma with a strongly positive human epidermal growth factor receptor 2 (HER2) score (3+). She was diagnosed as having inflammatory breast cancer (IBC) (T4d N2M0, stage IIIb). The patient received primary systemic chemotherapy with 4 courses of epirubicin 75 mg/m(2) and cyclophosphamide 500 mg/m(2) every three weeks, then 12 courses of paclitaxel 80 mg/m(2) and trastuzumab 2 mg/kg (initially 4 mg/kg) weekly. Six months after the start of chemotherapy, a left modified radical mastectomy with axillary dissection was performed. No cancer cells in the breast specimen and no metastases to the axillary nodes were observed, so the therapeutic effect was determined as a pathological complete response (pCR). This report suggests that combination therapy with epirubicin and cyclophosphamide followed by trastuzumab and paclitaxel was useful for HER2-positive IBC.


    • 6 February 2009
      • Vol. 28, 4137-42

    Epirubicin and cyclophosphamide followed by docetaxel as primary systemic chemotherapy in locally advanced breast cancer.

    by Akira Hirano, Tadao Shimizu, Osamu Watanabe, Jun Kinoshita, Kiyomi Kimura, Mari Kamimura, Kaoru Domoto, Motohiko Aiba, Kenji Ogawa

    The aim of this study was to evaluate the activity and toxicity of epirubicin and cyclophosphamide (EC) followed by docetaxel as primary systemic chemotherapy (PST) in locally advanced breast cancer. In this phase II trial, 46 patients with locally advanced breast cancer (T > 3 cm or N > 1) received epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) every 3 weeks for four cycles, followed by docetaxel (70 mg/m2) every 3 weeks for four cycles. Primary endpoints were pathological and objective response in the breast and axilla, and toxicities. The clinical response rate was 80.4% (95% confidence interval, 68.9-91.9%). Pathological response evaluation revealed 6 complete responses (CR: 13.0%). Patients with ER-negative tumors had a significantly higher rate of pathological CR than the others (33.3% vs. 3.2%; p = 0.0105). Febrile neutropenia occurred in 4 patients (8.7%). EC followed by docetaxel is an active and well-tolerated treatment as PST for locally advanced breast cancer.


  • A CASE OF MATRIX-PRODUCING CARCINOMA OF THE BREAST IN WHICH CT EXAMINATION WAS USEFUL

    by Hisaki Yamashita, Tadao Shimizu, Akira Hirano, Hiroshi Imamura, Kenji Ogawa, Motohiko Aiba